Soluble CD40L Is a Useful Marker to Predict Future Strokes in Patients With Minor Stroke and Transient Ischemic Attack

Stroke. 2015 Jul;46(7):1990-2. doi: 10.1161/STROKEAHA.115.008685. Epub 2015 May 26.


Background and purpose: Elevated soluble CD40 ligand (sCD40L) was shown to be related to cardiovascular events, but the role of sCD40L in predicting recurrent stroke remains unclear.

Methods: Baseline sCD40L levels were measured in 3044 consecutive patients with acute minor stroke and transient ischemic attack, who had previously been enrolled in the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial. Cox proportional-hazards model was used to assess the association of sCD40L with recurrent stroke.

Results: Patients in the top tertile of sCD40L levels had increased risk of recurrent stroke comparing with those in the bottom tertile, after adjusted for conventional confounding factors (hazard ratio, 1.49; 95% confidence interval, 1.11-2.00; P=0.008). The patients with elevated levels of both sCD40L and high-sensitive C-reactive protein also had increased risk of recurrent stroke (hazard ratio, 1.81; 95% confidence interval, 1.23-2.68; P=0.003).

Conclusions: Elevated sCD40L levels independently predict recurrent stroke in patients with minor stroke and transient ischemic attack.

Clinical trial registration: URL: Unique identifier: NCT00979589.

Keywords: CD40 ligand; ischemic attack, transient; prognosis; stroke.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • CD40 Ligand / blood*
  • Female
  • Follow-Up Studies
  • Forecasting
  • Humans
  • Ischemic Attack, Transient / blood*
  • Ischemic Attack, Transient / diagnosis*
  • Ischemic Attack, Transient / epidemiology
  • Male
  • Predictive Value of Tests
  • Recurrence
  • Risk Factors
  • Stroke / blood*
  • Stroke / diagnosis*
  • Stroke / epidemiology


  • Biomarkers
  • CD40 Ligand

Associated data